vs
Phathom Pharmaceuticals, Inc.（PHAT）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
RE/MAX Holdings, Inc.的季度营收约是Phathom Pharmaceuticals, Inc.的1.2倍（$71.1M vs $57.6M），Phathom Pharmaceuticals, Inc.同比增速更快（94.1% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $-167.0M）
Phathom Pharmaceuticals是一家临床阶段生物制药公司，专注于研发和商业化胃肠道疾病的创新疗法，其核心候选产品针对酸相关疾病、炎症性肠病等适应症，主要服务北美及欧洲地区的患者群体。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
PHAT vs RMAX — 直观对比
营收规模更大
RMAX
是对方的1.2倍
$57.6M
营收增速更快
PHAT
高出96.0%
-1.8%
自由现金流更多
RMAX
多$200.5M
$-167.0M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $57.6M | $71.1M |
| 净利润 | — | $1.4M |
| 毛利率 | 86.7% | — |
| 营业利润率 | — | 13.1% |
| 净利率 | — | 2.0% |
| 营收同比 | 94.1% | -1.8% |
| 净利润同比 | 71.6% | -75.2% |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PHATRMAX
| Q4 25 | $57.6M | $71.1M | ||
| Q3 25 | $49.5M | $73.2M | ||
| Q2 25 | $39.5M | $72.8M | ||
| Q1 25 | $28.5M | $74.5M | ||
| Q4 24 | $29.7M | $72.5M | ||
| Q3 24 | $16.4M | $78.5M | ||
| Q2 24 | $7.3M | $78.5M | ||
| Q1 24 | — | $78.3M |
净利润PHATRMAX
| Q4 25 | — | $1.4M | ||
| Q3 25 | $-30.0M | $4.0M | ||
| Q2 25 | $-75.8M | $4.7M | ||
| Q1 25 | $-94.3M | $-2.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | $-85.6M | $966.0K | ||
| Q2 24 | $-91.4M | $3.7M | ||
| Q1 24 | — | $-3.4M |
毛利率PHATRMAX
| Q4 25 | 86.7% | — | ||
| Q3 25 | 87.5% | — | ||
| Q2 25 | 87.2% | — | ||
| Q1 25 | 86.9% | — | ||
| Q4 24 | 87.1% | — | ||
| Q3 24 | 85.6% | — | ||
| Q2 24 | 81.2% | — | ||
| Q1 24 | — | — |
营业利润率PHATRMAX
| Q4 25 | — | 13.1% | ||
| Q3 25 | -30.8% | 25.0% | ||
| Q2 25 | -151.7% | 19.3% | ||
| Q1 25 | -276.5% | 7.2% | ||
| Q4 24 | — | 5.9% | ||
| Q3 24 | -433.0% | 19.4% | ||
| Q2 24 | -1055.4% | 20.6% | ||
| Q1 24 | — | 5.8% |
净利率PHATRMAX
| Q4 25 | — | 2.0% | ||
| Q3 25 | -60.5% | 5.4% | ||
| Q2 25 | -191.9% | 6.4% | ||
| Q1 25 | -330.7% | -2.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | -523.3% | 1.2% | ||
| Q2 24 | -1248.6% | 4.7% | ||
| Q1 24 | — | -4.3% |
每股收益（稀释后）PHATRMAX
| Q4 25 | — | — | ||
| Q3 25 | $-0.41 | — | ||
| Q2 25 | $-1.05 | — | ||
| Q1 25 | $-1.31 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.32 | — | ||
| Q2 24 | $-1.56 | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $130.0M | $118.7M |
| 总债务越低越好 | $209.1M | $432.2M |
| 股东权益账面价值 | $-438.2M | $452.4M |
| 总资产 | $259.1M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资PHATRMAX
| Q4 25 | $130.0M | $118.7M | ||
| Q3 25 | $135.2M | $107.5M | ||
| Q2 25 | $149.6M | $94.3M | ||
| Q1 25 | $212.3M | $89.1M | ||
| Q4 24 | $297.3M | $96.6M | ||
| Q3 24 | $334.7M | $83.8M | ||
| Q2 24 | $276.2M | $66.1M | ||
| Q1 24 | — | $82.1M |
总债务PHATRMAX
| Q4 25 | $209.1M | $432.2M | ||
| Q3 25 | $207.1M | $433.3M | ||
| Q2 25 | $205.1M | $434.4M | ||
| Q1 25 | $203.2M | $435.3M | ||
| Q4 24 | $201.4M | $436.2M | ||
| Q3 24 | $175.7M | $437.2M | ||
| Q2 24 | $174.4M | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益PHATRMAX
| Q4 25 | $-438.2M | $452.4M | ||
| Q3 25 | $-422.5M | $448.1M | ||
| Q2 25 | $-405.8M | $442.4M | ||
| Q1 25 | $-338.4M | $433.5M | ||
| Q4 24 | $-253.6M | $429.5M | ||
| Q3 24 | $-187.1M | $423.1M | ||
| Q2 24 | $-233.8M | $418.4M | ||
| Q1 24 | — | $412.0M |
总资产PHATRMAX
| Q4 25 | $259.1M | $582.5M | ||
| Q3 25 | $240.3M | $582.2M | ||
| Q2 25 | $250.2M | $574.8M | ||
| Q1 25 | $294.2M | $571.4M | ||
| Q4 24 | $378.3M | $581.6M | ||
| Q3 24 | $387.0M | $578.6M | ||
| Q2 24 | $319.4M | $571.4M | ||
| Q1 24 | — | $566.7M |
负债/权益比PHATRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-166.8M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $-167.0M | $33.5M |
| 自由现金流率自由现金流/营收 | -290.0% | 47.1% |
| 资本支出强度资本支出/营收 | 0.4% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $-328.9M | $56.8M |
8季度趋势，按日历期对齐
经营现金流PHATRMAX
| Q4 25 | $-166.8M | $40.9M | ||
| Q3 25 | $-14.1M | $17.7M | ||
| Q2 25 | $-62.7M | $4.6M | ||
| Q1 25 | $-84.9M | $5.7M | ||
| Q4 24 | $-266.8M | $59.7M | ||
| Q3 24 | $-63.6M | $17.6M | ||
| Q2 24 | $-70.7M | $15.9M | ||
| Q1 24 | — | $9.4M |
自由现金流PHATRMAX
| Q4 25 | $-167.0M | $33.5M | ||
| Q3 25 | $-14.1M | $16.4M | ||
| Q2 25 | $-62.8M | $2.9M | ||
| Q1 25 | $-84.9M | $4.0M | ||
| Q4 24 | $-266.9M | $53.0M | ||
| Q3 24 | $-63.6M | $16.3M | ||
| Q2 24 | $-70.8M | $14.0M | ||
| Q1 24 | — | $6.8M |
自由现金流率PHATRMAX
| Q4 25 | -290.0% | 47.1% | ||
| Q3 25 | -28.6% | 22.4% | ||
| Q2 25 | -159.0% | 4.0% | ||
| Q1 25 | -297.9% | 5.3% | ||
| Q4 24 | -899.8% | 73.2% | ||
| Q3 24 | -389.0% | 20.8% | ||
| Q2 24 | -966.2% | 17.8% | ||
| Q1 24 | — | 8.6% |
资本支出强度PHATRMAX
| Q4 25 | 0.4% | 10.4% | ||
| Q3 25 | 0.1% | 1.8% | ||
| Q2 25 | 0.2% | 2.2% | ||
| Q1 25 | 0.1% | 2.3% | ||
| Q4 24 | 0.5% | 9.1% | ||
| Q3 24 | 0.3% | 1.7% | ||
| Q2 24 | 0.6% | 2.4% | ||
| Q1 24 | — | 3.3% |
现金转化率PHATRMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PHAT
暂无分部数据
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
